Kevin J Clerkin1, Susan W Restaino1, Emmanuel Zorn2, Elena R Vasilescu3, Charles C Marboe3, Donna M Mancini4. 1. Department of Medicine, Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, New York. 2. Columbia Center for Translational Immunology, Columbia University College of Physicians and Surgeons, New York, New York. 3. Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, New York. 4. Department of Medicine, Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, New York. Electronic address: dmm31@cumc.columbia.edu.
Abstract
BACKGROUND: Antibody-mediated rejection (AMR) has been associated with increased death and cardiac allograft vasculopathy (CAV). Early studies suggested that late AMR was rarely associated with graft dysfunction, whereas recent reports have demonstrated an association with increased mortality. We investigated the timing of AMR and its association with graft dysfunction, death, and CAV. METHODS: This retrospective cohort study identified all adult orthotopic heart transplant (OHT) recipients (N = 689) at Columbia University Medical Center from 2004 to 2013. There were 68 primary cases of AMR, which were stratified by early (< 1 year post-OHT) or late (> 1 year post-OHT) AMR. Kaplan-Meier survival analysis and modeling was performed with multivariable logistic regression and Cox proportional hazards regression. RESULTS: From January 1, 2004, through October 1, 2015, early AMR (median 23 days post-OHT) occurred in 43 patients and late AMR (median 1,084 days post-OHT) occurred in 25. Graft dysfunction was less common with early compared with late AMR (25.6% vs 56%, p = 0.01). Patients with late AMR had decreased post-AMR survival compared with early AMR (1 year: 80% vs 93%, 5 years: 51% vs 73%, p < 0.05). When stratified by graft dysfunction, only those with late AMR and graft dysfunction had worse survival (30 days: 79%, 1 year: 64%, 5 years: 36%; p < 0.006). The association remained irrespective of age, sex, donor-specific antibodies, left ventricular assist device use, reason for OHT, and recovery of graft function. Similarly, those with late AMR and graft dysfunction had accelerated development of de novo CAV (50% at 1 year; hazard ratio, 5.42; p = 0.009), whereas all other groups were all similar to the general transplant population. CONCLUSIONS: Late AMR is frequently associated with graft dysfunction. When graft dysfunction is present in late AMR, there is an early and sustained increased risk of death and rapid development of de novo CAV despite aggressive treatment.
BACKGROUND: Antibody-mediated rejection (AMR) has been associated with increased death and cardiac allograft vasculopathy (CAV). Early studies suggested that late AMR was rarely associated with graft dysfunction, whereas recent reports have demonstrated an association with increased mortality. We investigated the timing of AMR and its association with graft dysfunction, death, and CAV. METHODS: This retrospective cohort study identified all adult orthotopic heart transplant (OHT) recipients (N = 689) at Columbia University Medical Center from 2004 to 2013. There were 68 primary cases of AMR, which were stratified by early (< 1 year post-OHT) or late (> 1 year post-OHT) AMR. Kaplan-Meier survival analysis and modeling was performed with multivariable logistic regression and Cox proportional hazards regression. RESULTS: From January 1, 2004, through October 1, 2015, early AMR (median 23 days post-OHT) occurred in 43 patients and late AMR (median 1,084 days post-OHT) occurred in 25. Graft dysfunction was less common with early compared with late AMR (25.6% vs 56%, p = 0.01). Patients with late AMR had decreased post-AMR survival compared with early AMR (1 year: 80% vs 93%, 5 years: 51% vs 73%, p < 0.05). When stratified by graft dysfunction, only those with late AMR and graft dysfunction had worse survival (30 days: 79%, 1 year: 64%, 5 years: 36%; p < 0.006). The association remained irrespective of age, sex, donor-specific antibodies, left ventricular assist device use, reason for OHT, and recovery of graft function. Similarly, those with late AMR and graft dysfunction had accelerated development of de novo CAV (50% at 1 year; hazard ratio, 5.42; p = 0.009), whereas all other groups were all similar to the general transplant population. CONCLUSIONS: Late AMR is frequently associated with graft dysfunction. When graft dysfunction is present in late AMR, there is an early and sustained increased risk of death and rapid development of de novo CAV despite aggressive treatment.
Authors: Lars H Lund; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Anne I Dipchand; Samuel Goldfarb; Bronwyn J Levvey; Bruno Meiser; Joseph W Rossano; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2015-08-28 Impact factor: 10.247
Authors: Elaine F Reed; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Jon A Kobashigawa; Nancy L Reinsmoen; E Rene Rodriguez; Marlene Rose; Susan Stewart; Nicole Suciu-Foca; Adriana Zeevi; Michael C Fishbein Journal: J Heart Lung Transplant Date: 2006-02 Impact factor: 10.247
Authors: Gerald J Berry; Margaret M Burke; Claus Andersen; Patrick Bruneval; Marny Fedrigo; Michael C Fishbein; Martin Goddard; Elizabeth H Hammond; Ornella Leone; Charles Marboe; Dylan Miller; Desley Neil; Doris Rassl; Monica P Revelo; Alexandra Rice; E Rene Rodriguez; Susan Stewart; Carmela D Tan; Gayle L Winters; Lori West; Mandeep R Mehra; Annalisa Angelini Journal: J Heart Lung Transplant Date: 2013-12 Impact factor: 10.247
Authors: Aidan M Hodges; Haifa Lyster; Anne McDermott; Alexandra J Rice; John D Smith; Marlene L Rose; Nicholas R Banner Journal: Transplantation Date: 2012-03-27 Impact factor: 4.939
Authors: Paul J Michaels; Maria L Espejo; Jon Kobashigawa; Juan C Alejos; Caron Burch; Steve Takemoto; Elaine F Reed; Michael C Fishbein Journal: J Heart Lung Transplant Date: 2003-01 Impact factor: 10.247
Authors: Steven K Takemoto; Adriana Zeevi; Sandy Feng; Robert B Colvin; Stanley Jordan; Jon Kobashigawa; Jerzy Kupiec-Weglinski; Arthur Matas; Robert A Montgomery; Peter Nickerson; Jeffrey L Platt; Hamid Rabb; Richard Thistlethwaite; Dolly Tyan; Francis L Delmonico Journal: Am J Transplant Date: 2004-07 Impact factor: 8.086
Authors: Donna Mancini; Sean Pinney; Daniel Burkhoff; John LaManca; Silviu Itescu; Elizabeth Burke; Niloo Edwards; Mehmet Oz; Andrew R Marks Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: A Loupy; C Toquet; P Rouvier; T Beuscart; M C Bories; S Varnous; R Guillemain; S Pattier; C Suberbielle; P Leprince; C Lefaucheur; X Jouven; P Bruneval; J P Duong Van Huyen Journal: Am J Transplant Date: 2015-11-20 Impact factor: 8.086
Authors: Oluwatoyosi A Onwuemene; Steven C Grambow; Chetan B Patel; Robert J Mentz; Carmelo A Milano; Joseph G Rogers; Ara D Metjian; Gowthami M Arepally; Thomas L Ortel Journal: J Clin Apher Date: 2018-03-10 Impact factor: 2.821
Authors: Kevin J Clerkin; Maryjane A Farr; Susan W Restaino; Emmanuel Zorn; Farhana Latif; Elena R Vasilescu; Charles C Marboe; Paolo C Colombo; Donna M Mancini Journal: J Heart Lung Transplant Date: 2016-11-17 Impact factor: 10.247
Authors: Catarina Costa; Ana Filipa Amador; João Calvão; Roberto Pinto; Pedro Rodrigues Pereira; José Pinheiro Torres; Sandra Amorim; Filipe Macedo Journal: Int J Heart Fail Date: 2022-03-28
Authors: Debanjana Chatterjee; Carolina Moore; Baoshan Gao; Kevin J Clerkin; Sarah B See; David Shaked; Kortney Rogers; Sarah Nunez; Yokarla Veras; Linda Addonizio; Michael M Givertz; Yoshifumi Naka; Donna Mancini; Rodica Vasilescu; Charles Marboe; Susan Restaino; Joren C Madsen; Emmanuel Zorn Journal: J Heart Lung Transplant Date: 2017-09-28 Impact factor: 10.247
Authors: Benjamin S Mantell; Hector Cordero; Sarah B See; Kevin J Clerkin; Rodica Vasilescu; Charles C Marboe; Yoshifumi Naka; Susan Restaino; Paolo C Colombo; Linda J Addonizio; Maryjane A Farr; Emmanuel Zorn Journal: J Heart Lung Transplant Date: 2021-07-08 Impact factor: 10.247